Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225314387> ?p ?o ?g. }
- W4225314387 endingPage "554" @default.
- W4225314387 startingPage "554" @default.
- W4225314387 abstract "New treatment options are needed for patients with Lennox-Gastaut syndrome (LGS), a profoundly impairing, treatment-resistant, developmental and epileptic encephalopathy.To evaluate the efficacy and safety of fenfluramine in patients with LGS.This multicenter, double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted from November 27, 2017, to October 25, 2019, and had a 20-week trial duration. Patients were enrolled at 65 study sites in North America, Europe, and Australia. Included patients were aged 2 to 35 years with confirmed diagnosis of LGS and experienced 2 or more drop seizures per week during the 4-week baseline. Using a modified intent-to-treat method, data analysis was performed from November 27, 2017, to October 25, 2019. The database lock date was January 30, 2020, and the date of final report was September 11, 2021.Patients were randomized to receive either a 0.7-mg/kg/d or 0.2-mg/kg/d (maximum 26 mg/d) dose of fenfluramine or placebo. After titration (2-week period), patients were taking their randomized dose for 12 additional weeks.Primary efficacy end point was percentage change from baseline in drop seizure frequency in patients who received 0.7 mg/kg/d of fenfluramine vs placebo.A total of 263 patients (median [range] age, 13 [2-35] years; 146 male patients [56%]) were randomized to the 0.7-mg/kg/d fenfluramine group (n = 87), 0.2-mg/kg/d fenfluramine group (n = 89), or placebo group (n = 87). The median percentage reduction in frequency of drop seizures was 26.5 percentage points in the 0.7-mg/kg/d fenfluramine group, 14.2 percentage points in the 0.2-mg/kg/d fenfluramine group, and 7.6 percentage points in the placebo group. The trial met its primary efficacy end point: patients in the 0.7-mg/kg/d fenfluramine group achieved a -19.9 percentage points (95% CI, -31.0 to -8.7 percentage points; P = .001) estimated median difference in drop seizures from baseline vs placebo. More patients in the 0.7-mg/kg/d fenfluramine group achieved a 50% or greater response (22 of 87 [25%]; P = .02) vs placebo (9 of 87 [10%]). Site investigators and caregivers gave a much improved or very much improved rating on the Clinical Global Impression of Improvement scale to more patients in the 0.7-mg/kg/d fenfluramine group than patients in the placebo group (21 [26%] vs 5 [6%]; P = .001). The seizure subtype that appeared most responsive to fenfluramine was generalized tonic-clonic seizure (120 of 263 [46%]), with a decrease in frequency of 45.7% in the 0.7-mg/kg/d fenfluramine group and 58.2% in the 0.2-mg/kg/d fenfluramine group compared with an increase of 3.7% in the placebo group. Most common treatment-emergent adverse events included decreased appetite (59 [22%]), somnolence (33 [13%]), and fatigue (33 [13%]). No cases of valvular heart disease or pulmonary arterial hypertension were observed.Results of this trial showed that, in patients with LGS, fenfluramine compared with placebo provided a significantly greater reduction in drop seizures and may be a particularly advantageous choice in patients who experience generalized tonic-clonic seizures.ClinicalTrials.gov Identifier: NCT03355209." @default.
- W4225314387 created "2022-05-05" @default.
- W4225314387 creator A5008350546 @default.
- W4225314387 creator A5009823256 @default.
- W4225314387 creator A5009870571 @default.
- W4225314387 creator A5026329899 @default.
- W4225314387 creator A5031681045 @default.
- W4225314387 creator A5032248849 @default.
- W4225314387 creator A5033173589 @default.
- W4225314387 creator A5041159807 @default.
- W4225314387 creator A5041482763 @default.
- W4225314387 creator A5045272621 @default.
- W4225314387 creator A5047530013 @default.
- W4225314387 creator A5052410990 @default.
- W4225314387 creator A5056594447 @default.
- W4225314387 creator A5066336399 @default.
- W4225314387 creator A5082410934 @default.
- W4225314387 creator A5084704668 @default.
- W4225314387 creator A5087393333 @default.
- W4225314387 creator A5091847660 @default.
- W4225314387 date "2022-06-01" @default.
- W4225314387 modified "2023-10-18" @default.
- W4225314387 title "Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome" @default.
- W4225314387 cites W1527516299 @default.
- W4225314387 cites W2110804937 @default.
- W4225314387 cites W2137728866 @default.
- W4225314387 cites W2169966598 @default.
- W4225314387 cites W2275720509 @default.
- W4225314387 cites W2596598505 @default.
- W4225314387 cites W2604155526 @default.
- W4225314387 cites W2624258472 @default.
- W4225314387 cites W2760749448 @default.
- W4225314387 cites W2767480397 @default.
- W4225314387 cites W2785059893 @default.
- W4225314387 cites W2804921146 @default.
- W4225314387 cites W2889968052 @default.
- W4225314387 cites W2989575580 @default.
- W4225314387 cites W2995886081 @default.
- W4225314387 cites W2996672198 @default.
- W4225314387 cites W3011777852 @default.
- W4225314387 cites W3116439139 @default.
- W4225314387 cites W3165147113 @default.
- W4225314387 cites W3189752156 @default.
- W4225314387 cites W3192885085 @default.
- W4225314387 cites W3195153769 @default.
- W4225314387 cites W3210797596 @default.
- W4225314387 cites W4240359399 @default.
- W4225314387 cites W4248815629 @default.
- W4225314387 cites W4249521147 @default.
- W4225314387 doi "https://doi.org/10.1001/jamaneurol.2022.0829" @default.
- W4225314387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35499850" @default.
- W4225314387 hasPublicationYear "2022" @default.
- W4225314387 type Work @default.
- W4225314387 citedByCount "30" @default.
- W4225314387 countsByYear W42253143872021 @default.
- W4225314387 countsByYear W42253143872022 @default.
- W4225314387 countsByYear W42253143872023 @default.
- W4225314387 crossrefType "journal-article" @default.
- W4225314387 hasAuthorship W4225314387A5008350546 @default.
- W4225314387 hasAuthorship W4225314387A5009823256 @default.
- W4225314387 hasAuthorship W4225314387A5009870571 @default.
- W4225314387 hasAuthorship W4225314387A5026329899 @default.
- W4225314387 hasAuthorship W4225314387A5031681045 @default.
- W4225314387 hasAuthorship W4225314387A5032248849 @default.
- W4225314387 hasAuthorship W4225314387A5033173589 @default.
- W4225314387 hasAuthorship W4225314387A5041159807 @default.
- W4225314387 hasAuthorship W4225314387A5041482763 @default.
- W4225314387 hasAuthorship W4225314387A5045272621 @default.
- W4225314387 hasAuthorship W4225314387A5047530013 @default.
- W4225314387 hasAuthorship W4225314387A5052410990 @default.
- W4225314387 hasAuthorship W4225314387A5056594447 @default.
- W4225314387 hasAuthorship W4225314387A5066336399 @default.
- W4225314387 hasAuthorship W4225314387A5082410934 @default.
- W4225314387 hasAuthorship W4225314387A5084704668 @default.
- W4225314387 hasAuthorship W4225314387A5087393333 @default.
- W4225314387 hasAuthorship W4225314387A5091847660 @default.
- W4225314387 hasBestOaLocation W42253143871 @default.
- W4225314387 hasConcept C118552586 @default.
- W4225314387 hasConcept C126322002 @default.
- W4225314387 hasConcept C142724271 @default.
- W4225314387 hasConcept C168563851 @default.
- W4225314387 hasConcept C170493617 @default.
- W4225314387 hasConcept C187212893 @default.
- W4225314387 hasConcept C203092338 @default.
- W4225314387 hasConcept C204787440 @default.
- W4225314387 hasConcept C27081682 @default.
- W4225314387 hasConcept C2775864247 @default.
- W4225314387 hasConcept C2778186239 @default.
- W4225314387 hasConcept C2779307984 @default.
- W4225314387 hasConcept C2779638493 @default.
- W4225314387 hasConcept C42219234 @default.
- W4225314387 hasConcept C71924100 @default.
- W4225314387 hasConceptScore W4225314387C118552586 @default.
- W4225314387 hasConceptScore W4225314387C126322002 @default.
- W4225314387 hasConceptScore W4225314387C142724271 @default.
- W4225314387 hasConceptScore W4225314387C168563851 @default.
- W4225314387 hasConceptScore W4225314387C170493617 @default.
- W4225314387 hasConceptScore W4225314387C187212893 @default.